Comparative Pharmacology
Head-to-head clinical analysis: METROGEL VAGINAL versus METROLOTION.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METROGEL VAGINAL versus METROLOTION.
METROGEL-VAGINAL vs METROLOTION
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metronidazole, a nitroimidazole antimicrobial, undergoes reduction by bacterial nitroreductases to form cytotoxic intermediates that disrupt DNA helical structure, inhibiting nucleic acid synthesis and causing bacterial cell death.
Metrolotion is a formulation of metronidazole, a nitroimidazole antibiotic. Its exact mechanism is not fully understood, but it is believed to involve reduction of the nitro group in anaerobic bacteria and protozoa, leading to DNA disruption and cell death. It also has anti-inflammatory and immunosuppressive properties, possibly by inhibiting neutrophil chemotaxis and reactive oxygen species.
One applicatorful (5 g of 0.75% gel) intravaginally once daily, usually at bedtime, for 5 days.
Topical metronidazole (Metrolotion) 1%: Apply a thin layer to affected areas once daily.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (prolonged in hepatic impairment; half-life may exceed 20 hours in severe hepatic disease)
Terminal elimination half-life is 18-24 hours; allows once-daily dosing.
Renal: 60-80% unchanged; fecal/biliary: 6-15%
Renal: 70% as unchanged drug; biliary/fecal: 30% as metabolites.
Category C
Category C
Antibiotic (Nitroimidazole)
Antibiotic (Nitroimidazole)